Clopidogrel dosing and role of genetics: ELEVATE-TIMI 56 trial: Difference between revisions
Jump to navigation
Jump to search
(/* ELEVATE-TIMI 56 trial {{cite journal| author=Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ et al.| title=Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiov) |
|||
| Line 6: | Line 6: | ||
==ELEVATE-TIMI 56 trial <ref name="pmid22088980">{{cite journal| author=Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ et al.| title=Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. | journal=JAMA | year= 2011 | volume= 306 | issue= 20 | pages= 2221-8 | pmid=22088980 | doi=10.1001/jama.2011.1703 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22088980 }} </ref> == | ==ELEVATE-TIMI 56 trial <ref name="pmid22088980">{{cite journal| author=Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ et al.| title=Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. | journal=JAMA | year= 2011 | volume= 306 | issue= 20 | pages= 2221-8 | pmid=22088980 | doi=10.1001/jama.2011.1703 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22088980 }} </ref> == | ||
* '''Hypothesis''' - | * '''Hypothesis''' - To see whether increasing the dose of clopidogrel to 300 mg / day rather than the standard 75 mg / day maintenance dose improves outcomes in patients with loss-of-function CYP2C19 genotypes. | ||
* '''Study design''' | * '''Study design''' | ||
** '''Patient population''' | ** '''Patient population''' | ||
*** Multicenter, randomized, double-blind trial | *** Multicenter, randomized, double-blind trial | ||
*** Duration of study - 1 years | *** Duration of study - 1 years | ||
*** Intervention - | *** Intervention - Maintenance doses of clopidogrel for 4 treatment periods, (each treatment period lasted 14 days). 247 noncarriers received 75 and 150 mg daily of clopidogrel (2 periods each), and 86 carriers (80 heterozygotes, 6 homozygotes) received 75, 150, 225, and 300 mg daily. | ||
*** Primary end point - | *** Primary end point - Platelet function test results and adverse events. | ||
* '''Limitations''' | * '''Limitations''' | ||
Revision as of 14:54, 25 November 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
The results of the ELEVATE-TIMI 56 trial were recently presented in AHA 2011 held at Orlando, Florida.
ELEVATE-TIMI 56 trial [1]
- Hypothesis - To see whether increasing the dose of clopidogrel to 300 mg / day rather than the standard 75 mg / day maintenance dose improves outcomes in patients with loss-of-function CYP2C19 genotypes.
- Study design
- Patient population
- Multicenter, randomized, double-blind trial
- Duration of study - 1 years
- Intervention - Maintenance doses of clopidogrel for 4 treatment periods, (each treatment period lasted 14 days). 247 noncarriers received 75 and 150 mg daily of clopidogrel (2 periods each), and 86 carriers (80 heterozygotes, 6 homozygotes) received 75, 150, 225, and 300 mg daily.
- Primary end point - Platelet function test results and adverse events.
- Patient population
- Limitations
- Results -
- Conclusions
References
- ↑ Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ; et al. (2011). "Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease". JAMA. 306 (20): 2221–8. doi:10.1001/jama.2011.1703. PMID 22088980.